Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra McGregor

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Science (New York, N.Y.)|October 21, 2017
From patients to partnersPeter DelNero, Alexandra McGregor
Bioorganic & Medicinal Chemistry Letters|November 19, 2003
New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chainsMichael B Gravestock, David G Acton, Michael J Betts, et al.
Molecular Cancer Therapeutics|June 11, 2009
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenograftsKate F Byth, Andrew Thomas, Gareth Hughes, et al.
Bioorganic & Medicinal Chemistry Letters|November 11, 2008
The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosingClifford D Jones, David M Andrews, Andrew J Barker, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Science (New York, N.Y.)|October 21, 2017
From patients to partnersPeter DelNero, Alexandra McGregor
Bioorganic & Medicinal Chemistry Letters|November 19, 2003
New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chainsMichael B Gravestock, David G Acton, Michael J Betts, et al.
Molecular Cancer Therapeutics|June 11, 2009
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenograftsKate F Byth, Andrew Thomas, Gareth Hughes, et al.
Bioorganic & Medicinal Chemistry Letters|November 11, 2008
The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosingClifford D Jones, David M Andrews, Andrew J Barker, et al.
Pageof 1